Zentalis Pharmaceuticals (ZNTL) Institutional Ownership

During the previous two years, 149 institutional investors and hedge funds held shares of Zentalis Pharmaceuticals. The most heavily invested institutionals were Matrix Capital Management Company LP ($393.81M), Eventide Asset Management LLC ($175.13M), Vanguard Group Inc. ($69.32M), Decheng Capital Management III Cayman LLC ($59.23M), Capital International Investors ($42.72M), Avidity Partners Management LP ($42.13M), and Wellington Management Group LLP ($38.46M).Learn more on ZNTL's institutional investors.

Of the 128 institutional investors that purchased Zentalis Pharmaceuticals stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Matrix Capital Management Company LP ($4.76M), Eventide Asset Management LLC ($4.68M), Decheng Capital LLC ($3.07M), Millennium Management LLC ($2.18M), Acadian Asset Management LLC ($1.61M), Cormorant Asset Management LP ($1.10M), and Integral Health Asset Management LLC ($1.05M).

Institutional investors have bought a total of 32,963,855 shares in the last 24 months. This purchase volume represents approximately $403.96M in transactions.

Of the 55 institutional investors that sold Zentalis Pharmaceuticals stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: FMR LLC ($4.68M), State Street Corp ($1.81M), Federated Hermes Inc. ($1.59M), Decheng Capital LLC ($1.09M), Vanguard Group Inc. ($951.83K), Bank of America Corp DE ($559.54K), and Woodline Partners LP ($524.70K).

Institutional investors have sold a total of 16,385,882 shares in the last 24 months. This volume of shares sold represents approximately $122.82M in transactions.